GRANULES

What Granules India promised, and what happened

Every commitment management made on a call, tracked from the quarter it was made — reaffirmed, revised, diluted or quietly dropped.

Guidance record · Q1 FY27

what the last two calls moved 26 tracked 7 delivered 6 missed 13 open
  • EBITDA Margin delivered said Q1 FY25 Promised: above 20% and improving Q1 FY27: Q1 FY27 margin was 22.9%, down QoQ but up 256 bps YoY, comfortably above the 20% target.
  • Production Disruption Duration missed said Q4 FY25 Promised: slowdown on operation in Gagillapur will continue for a quarter or two Q1 FY27: The facility is still awaiting FDA clearance in Q1 FY27, far exceeding the original 'quarter or two' guidance.
  • Oncology Product Launches revised down said Q1 FY25 Promised: start in FY26 Q1 FY27: Management reiterated a delayed timeline in Q1 FY27, with the first self-developed oncology product now slated for launch in FY28-29, confirming the original FY26 target was missed.

The rest of the ledger

Above is what the last two calls moved. Pro opens all 26 tracked commitments for Granules India — every quarter's revision, the source quote behind each one, and the topics management has stopped answering.

See what Pro opens